ArticleBiochemical and biophysical research communications2026
Interaction of cytochrome P450 3A4 with the hydrophilic ligand tetraethylene glycol.
Article in Biochemical and biophysical research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Human cytochrome P450 3A4 (CYP3A4) is a clinically important drug-metabolizing enzyme that can oxidize a wide range of structurally diverse compounds. Due to hydrophobic nature of the active site, CYP3A4 preferably binds and biotransforms lipophilic compounds. However, small hydrophilic molecules can also interact with CYP3A4 and affect its activity via mechanisms that are incompletely understood, partly due to limited structural information. This paper describes the high-resolution X-ray structure of CYP3A4 complexed with the heme-ligating imidazole and two molecules of tetraethylene glycol (TEG1 and TEG2) originating from the crystallization solution. TEG1 binds to the active site in a curled conformation stabilized by multiple direct and water-mediated H-bonds with S119, R212, R372 and the heme propionate. TEG2, in turn, docks on the outer surface in two alternative conformations, strengthening intermolecular contacts in the crystal lattice. In vitro studies showed that, when bound to the active site, TEG can modulate substrate binding and functional activity of CYP3A4. Because TEG is present in polyethylene glycol mixtures widely used in food and pharmaceutical industries and has high gastrointestinal absorption, there is a possibility of in vivo CYP3A4-TEG complex formation that could affect intestinal drug metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.